Published in Drug Law Weekly, November 14th, 2006
The FTC issued the second request in connection with its review of Watson's pending acquisition of Andrx Corp. (ADRX) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). Andrx had previously submitted its certificate of substantial compliance.
Based on Watson's submission of its certificate of substantial compliance, Watson believes the waiting period imposed under...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.